Source: CureToday articles
Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk HER2-positive early-stage breast cancer.
Recent Content
- Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review
- Expert: Navigating the Next Decade of Market Growth and Innovation for Biosimilars
- Honoring a Healer: Personal Care With National Impact
- Breaking Barriers: Why Increasing Lung Screening is Critical
- GLP-1 Drugs Show Promise in Lowering Health Care Costs, Report Says
- Asembia AXS25: Emotional Support Transforms Specialty Pharmacy Patient Care
- LCI Shows Support for Lung Cancer Research Funding at GO2 Voices Summit
- Managing Lung Inflammation After Chemoradiation and Tagrisso
- Lung Cancer Initiative Names New Chief Scientific Officer and Announces 2025 Research Award Recipients
- How Quitting Smoking After a Cancer Diagnosis Can Boost Survival